MX9400800A - Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion. - Google Patents

Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion.

Info

Publication number
MX9400800A
MX9400800A MX9400800A MX9400800A MX9400800A MX 9400800 A MX9400800 A MX 9400800A MX 9400800 A MX9400800 A MX 9400800A MX 9400800 A MX9400800 A MX 9400800A MX 9400800 A MX9400800 A MX 9400800A
Authority
MX
Mexico
Prior art keywords
cognition
activator
complex
composition
hci
Prior art date
Application number
MX9400800A
Other languages
English (en)
Inventor
Galen W Radebaugh
Mahdi B Fawzi
Hua-Pin Huang
Scott C Wootton
Thomas N Julian
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MX9400800A publication Critical patent/MX9400800A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se presenta una composición sólida para estabilizar la dosificación del activador de la cognición CI-979 HC1 mediante la formación de un complejo con polidextrosa cíclica. En particular, se ha encontrado que composiciones con HPßCD estabilizan CI-979 HC1 aún en presencia de otros excipientes tales como carbonato de sodio. Formulaciones farmacéuticas para el tratamiento de desórdenes de la cognición en seres humanos se basan en la estabilización de CI-979 HC1 y de polidextrosa cíclica, incluyendo cantidades apropiadas de otros excipientes o compuestos conocidos en la técnica de la formulación. Esta invención se refiere en términos generales a una composición estabilizada y especialmente a un complejo de almacenamiento sólido de oximas basadas en piridina. Además, tal composición es útil para estabilizar el fármaco de activación de la cognición CI-979 HC1, contra pérdidas debido a degradación o evaporación.
MX9400800A 1993-02-01 1994-01-31 Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion. MX9400800A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/012,107 US5362860A (en) 1993-02-01 1993-02-01 Neutral stabilization complex for CI-979 HCl, a cognition activator

Publications (1)

Publication Number Publication Date
MX9400800A true MX9400800A (es) 1994-08-31

Family

ID=21753423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9400800A MX9400800A (es) 1993-02-01 1994-01-31 Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion.

Country Status (6)

Country Link
US (1) US5362860A (es)
EP (1) EP0681471A1 (es)
JP (1) JPH08506119A (es)
CA (1) CA2150135A1 (es)
MX (1) MX9400800A (es)
WO (1) WO1994017801A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA937382B (en) * 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
KR100351707B1 (ko) * 1994-12-30 2002-11-02 에스케이케미칼주식회사 플라티늄(II)착화합물과히드록시프로필β-사이클로덱스트린의복합체
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
WO2002017877A2 (en) * 2000-08-31 2002-03-07 Universiteit Gent Controlled release pharmaceutical pellet compositions for reducing side effects of drugs
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ608239A (en) 2010-09-13 2015-05-29 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU558787B2 (en) * 1981-01-23 1987-02-12 Wellcome Foundation Limited, The Inclusion complexes of cyclodextrins and cardiac clycosides
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4710508A (en) * 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
IT1203971B (it) * 1987-04-24 1989-02-23 Roussel Maestretti Spa Derivati di 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro applicazione come medicamenti
CA2054664C (en) * 1990-11-30 1996-06-11 Nesbitt D. Brown Hydrolytic stabilizer for unstable organic ions

Also Published As

Publication number Publication date
WO1994017801A1 (en) 1994-08-18
EP0681471A1 (en) 1995-11-15
US5362860A (en) 1994-11-08
CA2150135A1 (en) 1994-08-18
JPH08506119A (ja) 1996-07-02

Similar Documents

Publication Publication Date Title
MX9400800A (es) Un complejo de estabilizacion neutro para ci-979 hci, un activador de la cognicion.
ES2129048T3 (es) Composicion estabilizada de hormona paratiroide.
CY1112963T1 (el) Σταθερες φαρμακευτικες συνθεσεις περιεχουσες 7-υποκατεστημενα-3,5-διυδροξυεπτανοϊκα οξεα ή 7-υποκατεστημενα-3,5-διυδροξυεπτενοϊκα οξεα
DE60228954D1 (en) Pyruvatderivate
AR018286A1 (es) Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
MX9400801A (es) Agentes colinergicos de oxima de tetrahidropiridinna o-substituidos estabilizados con almidon.
BR112022013009A2 (pt) Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
TR200103153T2 (tr) Yeni bileşimler
EA200701986A1 (ru) Улучшенные составы фенофибрата, содержащие ментол или смесь пэг/полоксамера
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
BR0210744A (pt) Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
AR015347A1 (es) Uso de colina para la preparacion de un medicamento o formulacion nutricional para el tratamiento del shock endotoxico y composiciones nutricionales quecomprenden colina
ES2173124T3 (es) Composicion de dermatano sulfato utilizado como antitrombotico.
ES2074037T1 (es) Dimero de la lisozima y composiciones que lo contienen.
CO5261531A1 (es) Derivados de pleuromutilina y valnemulina usados para la fabricacion de un medicamento en el tratamiento transdermico de infecciones bacterianas en humanos y animales y composicion que los contiene
KR960700712A (ko) 벤조이미다졸 구충제와 메틸렌디옥시페닐 화합물을 포함하는 상승 화합물(synergistic compositions containing benzimidazole anthelmintics and methylenedioxyphenyl compounds)
BRPI0608395A2 (pt) composição farmacêutica sólida que compreende telitromicina
MX9207344A (es) Formulaciones mejoradas que tienen mejoradores hidrofobicos de penetracion transdermica y metodo para proveerla.
ES476427A1 (es) Procedimiento para preparar tetrahidro-1,3,5-triazina-2,6- dionas.
ES2182504T3 (es) Bifenilsulfonilcianamidas, procedimiento para su preparacion y su utilizacion como medicamento.
ES2083490T3 (es) 3,5-diyodo-l-tironina para la supresion de tsh y el tratamiento del bocio.
ES2113136T3 (es) Composiciones farmaceuticas de gemfibrozil y procedimiento para su preparacion.
ES2147796T3 (es) Composicion para el tratamiento o la prevencion del herpes.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees